Stem Cell Therapeutics

125 articles about Stem Cell Therapeutics

• Stem Cell Therapeutics Wraps Up $33 Million Financing Round

  12/16/2013

• Stem Cell Therapeutics Reorganizes, Names New Management Team

  12/7/2011

• Stem Cell Therapeutics Announces Outcome of End of Phase II Meeting With FDA and Provides a Corporate Update & 2011/12 Milestones

  12/27/2010

• Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to NTx(R)-265

  12/9/2010

• Executive Changes at Stem Cell Therapeutics; Alan Moore Will No Longer Be President and CEO and Allen Davidoff Will Become Chief Scientific Officer

  11/30/2010

• Stem Cell Therapeutics Announces Proceeds From Execution of Warrants

  11/3/2010

• Stem Cell Therapeutics Receives Request for Full TBI Proposal From the US Dept of Defense

  10/13/2010

• Stem Cell Therapeutics Receives FDA End of Phase II Meeting Date

  10/8/2010

• Stem Cell Therapeutics Announces Appointment of Chief Financial Officer

  10/1/2010

• Stem Cell Therapeutics Announces the Resignation of a Board of Director

  9/15/2010

• Stem Cell Therapeutics Announces Completion of Further Analysis of the Modified REGENESIS Stroke Data

  9/9/2010

• Stem Cell Therapeutics Announces Funding of the Traumatic Brain Injury (TBI) Clinical Study and Issuance of Stock Options

  8/30/2010

• Stem Cell Therapeutics Announces Funding of the Traumatic Brain Injury (TBI) Clinical Study and Issuance of Stock Options

  8/30/2010

• Stem Cell Therapeutics Announces Q2 2010 Financial Results

  8/26/2010

• Stem Cell Therapeutics: Traumatic Brain Injury (TBI) Clinical Study Gains IRB Approval at University of Calgary

  8/13/2010

• Stem Cell Therapeutics: Corporate Update

  8/10/2010

• Stem Cell Therapeutics To Cut Senior Jobs, Stock Drops

  6/25/2010

• Stem Cell Therapeutics Continues Its Validation Review of the Modified REGENESIS Phase IIb Stroke Trial

  6/17/2010

• Stem Cell Therapeutics Announces the Issuance of United States Patent

  6/8/2010

• Stem Cell Therapeutics Stroke Drug, NTx-265 Fails Phase 2 Trial

  5/25/2010